Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhan, Qiang
NCT05469685: Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication	Completed	4	914	RoW	Vonoprazan, Amoxicillin	Nanjing First Hospital, Nanjing Medical University	Helicobacter Pylori Infection	08/23	09/23
NCT05649540: Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori	Active, not recruiting	4	900	RoW	Vonoprazan, Amoxicillin	Nanjing First Hospital, Nanjing Medical University	Helicobacter Pylori Infection	12/24	12/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
NCT05654857: The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu	Recruiting	N/A	4000	RoW	PCR test in the stool	Nanjing First Hospital, Nanjing Medical University	Helicobacter Pylori Infection	08/23	08/23
Ding, Lixia
NCT05469685: Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication	Completed	4	914	RoW	Vonoprazan, Amoxicillin	Nanjing First Hospital, Nanjing Medical University	Helicobacter Pylori Infection	08/23	09/23
NCT05654857: The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu	Recruiting	N/A	4000	RoW	PCR test in the stool	Nanjing First Hospital, Nanjing Medical University	Helicobacter Pylori Infection	08/23	08/23